Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 studyMartin Hutchings, Pieternella J. Lugtenburg, Rogier Mous et al.|The Lancet|2021Cited by 337
Industry Perspective on First‐in‐Human and Clinical Pharmacology Strategies to Support Clinical Development of T‐Cell Engaging Bispecific Antibodies for Cancer TherapyPrathap Nagaraja Shastri, Alison Betts, Meric Ovacik et al.|Clinical Pharmacology & Therapeutics|2024Cited by 9